Literature DB >> 22971139

The association between levels of tissue inhibitor of metalloproteinase-1 with acute heart failure and left ventricular dysfunction in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention.

Monika Pavkova Goldbergova1, Jiri Parenica, Jiri Jarkovsky, Petr Kala, Martin Poloczek, Jan Manousek, Krystyna Kluz, Lenka Kubkova, Simona Littnerova, Martin Tesak, Ondrej Toman, Nikolas Pavek, Zdenka Cermakova, Josef Tomandl, Anna Vasku, Jindrich Spinar.   

Abstract

AIMS: Tissue inhibitors of metalloproteinase (TIMPs) bind to active matrix metalloproteinase (MMPs), and thereby inhibit their proteolytic activity. We investigated the role of polymorphisms in the gene for TIMP-1 and serum levels of TIMP-1 in association with postmyocardial infarction (MI), left ventricular (LV) dysfunction, and symptoms of acute heart failure (AHF) in patients treated with primary percutaneous coronary intervention.
METHODS: In total, 556 patients with STEMI were evaluated. Levels of TIMP-1 were measured at admission and 24 h after MI onset. The TIMP-1 exon 5 SNP rs4898 (F124F with T>C) located at X chromosome was assayed.
RESULTS: TIMP-1 levels were higher for men with AHF as well as for men with LV dysfunction (ejection fraction [EF]<40%). According to multivariate analysis, the TIMP-1 level was a factor with an independent negative relationship to EF and AHF in men. An independent relationship between exon 5 TIMP-1 gene polymorphism and EF, AHF or TIMP-1 level was not documented.
CONCLUSION: These results provide evidence that a higher level of circulating TIMP-1 is independently associated with worse EF and AHF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971139      PMCID: PMC3468114          DOI: 10.1089/gtmb.2012.0120

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  18 in total

Review 1.  Integrin signaling.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Science       Date:  1999-08-13       Impact factor: 47.728

Review 2.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

3.  Role of tissue inhibitors of metalloproteinase in diabetic nephropathy.

Authors:  M Kanauchi; H Nishioka; Y Nakashima; T Hashimoto; K Dohi
Journal:  Nihon Jinzo Gakkai Shi       Date:  1996-03

4.  Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition.

Authors:  John S Ikonomidis; Jennifer W Hendrick; Andrea M Parkhurst; Amanda R Herron; Patricia G Escobar; Kathryn B Dowdy; Robert E Stroud; Elizabeth Hapke; Michael R Zile; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01       Impact factor: 4.733

5.  Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.

Authors:  Carson S Webb; David D Bonnema; S Hinan Ahmed; Amy H Leonardi; Catherine D McClure; Leslie L Clark; Robert E Stroud; William C Corn; Laura Finklea; Michael R Zile; Francis G Spinale
Journal:  Circulation       Date:  2006-08-21       Impact factor: 29.690

6.  Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction.

Authors:  Dominic Kelly; Iain B Squire; Sohail Q Khan; Onkar Dhillon; Hafid Narayan; K H Ng; Paulene Quinn; Joan E Davies; Leong L Ng
Journal:  Am J Cardiol       Date:  2010-08-15       Impact factor: 2.778

7.  The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.

Authors:  Malcolm J West; Paul J Nestel; Adrienne C Kirby; Renate Schnabel; David Sullivan; R John Simes; Christine Pollicino; Edith Lubos; Thomas F Münzel; Harvey D White; Andrew M Tonkin; Christoph Bickel; Laurence Tiret; Stefan Blankenberg
Journal:  Eur Heart J       Date:  2008-02-22       Impact factor: 29.983

8.  Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm.

Authors:  Irene Hinterseher; Dietmar Krex; Eberhard Kuhlisch; Karl G Schmidt; Christian Pilarsky; Wolfgang Schneiders; Hans D Saeger; Hendrik Bergert
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

9.  Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease.

Authors:  Angel López-Cuenca; Francisco Marín; Vanessa Roldán; Vicente E Climent; Mariano Valdés; Gregory Y H Lip
Journal:  Int J Cardiol       Date:  2008-08-22       Impact factor: 4.164

10.  Epigenetic predisposition to expression of TIMP1 from the human inactive X chromosome.

Authors:  Catherine L Anderson; Carolyn J Brown
Journal:  BMC Genet       Date:  2005-09-29       Impact factor: 2.797

View more
  8 in total

Review 1.  Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors.

Authors:  Francis G Spinale; Francisco Villarreal
Journal:  Biochem Pharmacol       Date:  2014-04-26       Impact factor: 5.858

2.  Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes.

Authors:  Samira Saravani; Davood Yari; Ramin Saravani; Changiz Azadi Ahmadabadi
Journal:  Biomed Rep       Date:  2017-02-09

3.  Myocardial-specific ablation of Jumonji and AT-rich interaction domain-containing 2 (Jarid2) leads to dilated cardiomyopathy in mice.

Authors:  Eunjin Cho; HyunJun Kang; Dae-Ki Kang; Youngsook Lee
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

4.  TIMP-1 gene polymorphism: are genetics able to predict outcome of septic patients?

Authors:  Michael Behnes; Thomas Bertsch; Ursula Hoffmann
Journal:  Crit Care       Date:  2013-07-17       Impact factor: 9.097

5.  EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice.

Authors:  Augustin DuSablon; Susan Kent; Anita Coburn; Jitka Virag
Journal:  Cardiovasc Diabetol       Date:  2014-08-13       Impact factor: 9.951

6.  Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.

Authors:  Aline Tatiane Toneto; Luiz Alberto Ferreira Ramos; Emilianne Miguel Salomão; Rebeka Tomasin; Miguel Arcanjo Aereas; Maria Cristina Cintra Gomes-Marcondes
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-24       Impact factor: 12.910

7.  Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure.

Authors:  Evelise Regina Polina; Raquel Rosa Candebat Vallejo Araújo; Renan Cesar Sbruzzi; Andréia Biolo; Luís Eduardo Rohde; Nadine Clausell; Kátia Gonçalves Dos Santos
Journal:  Sci Rep       Date:  2018-06-21       Impact factor: 4.379

8.  Systems Genetics Approach to Biomarker Discovery: GPNMB and Heart Failure in Mice and Humans.

Authors:  Liang-Yu Lin; Sunny Chun Chang; Jim O'Hearn; Simon T Hui; Marcus Seldin; Pritha Gupta; Galyna Bondar; Mario Deng; Raimo Jauhiainen; Johanna Kuusisto; Markku Laakso; Janet S Sinsheimer; Arjun Deb; Christoph Rau; Shuxun Ren; Yibin Wang; Aldons J Lusis; Jessica J Wang; Adriana Huertas-Vazquez
Journal:  G3 (Bethesda)       Date:  2018-11-06       Impact factor: 3.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.